Myeloid Sarcoma: Evaluation of Histopathology, Immunoprofile and Cytogenetics
Introduction: Myeloid Sarcoma (MS), an uncommon tumour of immature myeloid blasts at extramedullary sites can be diagnostically challenging, if it is present de novo, precedes Acute Myeloid Leukaemia (AML) or Myeloproliferative Neoplasm (MPN). There are a few studies in literature with a substa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2021-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://www.jcdr.net/articles/PDF/14625/46395_CE[Ra1]_F[SK]_PF1(F_KM)_PFA(SHU)_PB(AS_KM)_PN(SHU).pdf |
| Summary: | Introduction: Myeloid Sarcoma (MS), an uncommon tumour
of immature myeloid blasts at extramedullary sites can be
diagnostically challenging, if it is present de novo, precedes
Acute Myeloid Leukaemia (AML) or Myeloproliferative
Neoplasm (MPN). There are a few studies in literature with
a substantial number of cases on clinicopathological,
Immunophenotypic (IPT) and Immunohistochemical (IHC)
characteristics of MS.
Aim: This study was aimed to analyse myeloid sarcoma in Indian
population according to the age, gender, site of involvement,
differential diagnoses, IHC, IPT and cytogenetics and to add
some to the existing knowledge.
Materials and Methods: The present cross-sectional
study was conducted at Gujarat Cancer Research Institute,
Ahmedabad, with a total of 38 patients, diagnosed over
past three years (January 2017 to December 2019). Clinical,
morphological, IHC, IPT and molecular data of those
38 patients were retrieved and analysed.
Results: Out of 38 cases, 16 (42.1%) and 13 (34.2%) cases
were previously diagnosed cases of AML and Chronic
Myeloid Leukaemia (CML) respectively. Nine patients (23.7%)
presented as de novo. Most common site was lymph node
(12/38, 31%), followed by breast, vertebra and other unusual
sites. Myeloperoxidase (MPO) (31/38, 81.5%), CD117 (25/35,
71.4%), CD45 (21/23, 91.3%), CD43 (14/22, 63.6%), CD68
(12/28, 42.8%), CD34 (15/37, 40.5%), CD33 (14/14, 100%),
CD13 (15/16, 93.7%), HLA-DR (11/12, 91.6%), CD99 (3/29,
10.3%) and Terminal deoxynucleotidyl Transferase (TdT) (1/9,
11.1%) were expressed by tumour cells. However, epithelial
mesenchymal, B and T lymphoid markers were negative. The
present study found inv(16) and t(8;21) in MS in known AML
patients. Among the known CML patients, two had variant
positive for t(9;22) {t(2;9;22) (p23;q34;q11.2)}.
Conclusion: Results of present study depicts that considering
MS in differential diagnosis in its de novo presentation is
necessary to prevent wrong diagnosis and help early treatment
of these patients. |
|---|---|
| ISSN: | 2249-782X 0973-709X |